Raghava Jagadeesh Salaka, Kala P Nair, Reddy Bedadala Sasibhushana, Deepashree Udayakumar, Bindu M Kutty, Bettadapura N Srikumar, Byrathnahalli S Shankaranarayana Rao
Temporal lobe epilepsy (TLE) is the most common form of focal epilepsies. Pharmacological treatment with anti-seizure drugs (ASDs) remains the mainstay in epilepsy management. Levetiracetam (LEV) is a second-generation ASD with a novel SV2A protein target and is indicated for treating focal epilepsies. While there is considerable literature in acute models, its effect in chronic epilepsy is less clear. Particularly, its effects on neuronal excitability, synaptic plasticity, adult hippocampal neurogenesis, and histological changes in chronic epilepsy have not been evaluated thus far, which formed the basis of the present study...
June 23, 2022: Neurochemistry International